IL65915A - Methods for producing a purified immunologically active tryptic peptide and for producing mono-specific antibodies to peptides prepared thereby - Google Patents

Methods for producing a purified immunologically active tryptic peptide and for producing mono-specific antibodies to peptides prepared thereby

Info

Publication number
IL65915A
IL65915A IL65915A IL6591582A IL65915A IL 65915 A IL65915 A IL 65915A IL 65915 A IL65915 A IL 65915A IL 6591582 A IL6591582 A IL 6591582A IL 65915 A IL65915 A IL 65915A
Authority
IL
Israel
Prior art keywords
producing
tryptic peptide
methods
specific antibodies
immunologically active
Prior art date
Application number
IL65915A
Other languages
English (en)
Other versions
IL65915A0 (en
Original Assignee
Goldenberg Milton David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldenberg Milton David filed Critical Goldenberg Milton David
Publication of IL65915A0 publication Critical patent/IL65915A0/xx
Publication of IL65915A publication Critical patent/IL65915A/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL65915A 1981-06-01 1982-05-31 Methods for producing a purified immunologically active tryptic peptide and for producing mono-specific antibodies to peptides prepared thereby IL65915A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/269,115 US4468457A (en) 1981-06-01 1981-06-01 Method for producing a CSAp tryptic peptide and anti-CSAp antibodies

Publications (2)

Publication Number Publication Date
IL65915A0 IL65915A0 (en) 1982-08-31
IL65915A true IL65915A (en) 1985-07-31

Family

ID=23025864

Family Applications (1)

Application Number Title Priority Date Filing Date
IL65915A IL65915A (en) 1981-06-01 1982-05-31 Methods for producing a purified immunologically active tryptic peptide and for producing mono-specific antibodies to peptides prepared thereby

Country Status (9)

Country Link
US (1) US4468457A (de)
EP (1) EP0066786B1 (de)
JP (1) JPS58501355A (de)
AT (1) ATE19792T1 (de)
AU (1) AU550306B2 (de)
CA (1) CA1183451A (de)
DE (1) DE3271119D1 (de)
IL (1) IL65915A (de)
WO (1) WO1982004263A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
US4962187A (en) * 1984-11-28 1990-10-09 Cota Biotech Common antigen for colorectal and mucinous ovarian tumors and process for isolating the same
ES8800604A1 (es) * 1985-04-22 1987-11-16 Hybritech Inc Un metodo para producir anticuerpos monoclonales
DK172686A (da) * 1985-04-22 1986-10-23 Hybritech Inc Antigen opnaaet ud fra humant vaev, fremgangsmaade til under anvendelse af antigenet at fremstille monoklonale antistoffer til diagnose og behandling af cancer, fremgangsmaade til paavisning af cancer, samt antistoffer mod antigenet
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
DK169987D0 (da) * 1987-04-03 1987-04-03 Jens Christian Jensenius Human tumor-associated antigen, ca-ou1
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US5925362A (en) * 1993-08-11 1999-07-20 Jenner Technologies Method to elicit an antitumor response with human prostate-specific antigen
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
ATE473242T1 (de) 1998-05-20 2010-07-15 Immunomedics Inc Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
DE60040556D1 (de) 1999-12-06 2008-11-27 Univ Illinois Hochaffine t-zellrezeptorproteine und verfahren
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
DE60129741T2 (de) * 2000-06-20 2008-04-30 Immunomedics, Inc. Zielgerichtete kombinationsimmuntherapie für krebs und infektionskrankheiten
US20020165149A1 (en) * 2000-12-08 2002-11-07 Kranz David M. Mutated class II major histocompatibility proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002303181A1 (en) * 2001-03-30 2002-10-15 University Of Massachusetts Morpholino imaging and therapy
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1517684B1 (de) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie
AU2003249742A1 (en) 2002-07-02 2004-01-23 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
MXPA05008222A (es) 2003-01-31 2005-10-05 Immunomedics Inc Metodos y composiciones para administrar agentes terapeuticos y de diagnostico.
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
EP1660519B1 (de) * 2003-07-29 2014-05-14 Immunomedics, Inc. Konjugate von 2-[18F]Fluor-2-desoxy-D-glucose und einem Peptid-Molekül
EP1733056B1 (de) 2004-03-31 2013-05-22 The General Hospital Corporation Verfahren zur bestimmung des ansprechens eines tumors auf behandlungen mit dem epidermalen wachstumsfaktor-rezeptor als target
CA2562729C (en) 2004-04-12 2013-11-12 Sandra Waugh Ruggles Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
PT2298815E (pt) 2005-07-25 2015-07-16 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
KR101476458B1 (ko) 2006-07-05 2015-01-05 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CN102448494B (zh) 2009-02-13 2016-02-03 免疫医疗公司 具有胞内可裂解的键的免疫共轭物
US8012770B2 (en) 2009-07-31 2011-09-06 Invisible Sentinel, Inc. Device for detection of antigens and uses thereof
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
MX2012004105A (es) 2009-10-09 2012-09-07 Invisible Sentinel Inc Dispositivo para deteccion de antigenos y usos del mismo.
EP2668501B1 (de) 2011-01-27 2019-06-12 Invisible Sentinel, Inc. Analytnachweisvorrichtungen, multiplex- und tischplattenvorrichtungen für den nachweis von analyten und verwendungen davon
WO2013096455A1 (en) 2011-12-20 2013-06-27 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
CN104919055B (zh) 2012-03-09 2018-06-19 因威瑟堡善迪诺有限公司 用单一信号检测多种分析物的方法和组合物
US10138479B2 (en) 2012-05-24 2018-11-27 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
NZ704157A (en) 2012-07-27 2018-08-31 Univ Illinois Engineering t-cell receptors
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
PL2900277T3 (pl) 2012-12-13 2022-05-16 Immunomedics, Inc. Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US9931412B2 (en) 2013-02-08 2018-04-03 The Regents Of The University Of Michigan Targeted theranostics
US20150050697A1 (en) 2013-08-19 2015-02-19 Abbott Molecular Inc. Nucleotide analogs
US10130590B2 (en) 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
CN105873945B (zh) 2013-11-22 2020-07-17 伊利诺伊州大学理事会 工程化的高亲和力人类t细胞受体
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
US10555926B2 (en) 2015-02-17 2020-02-11 Erasmus University Medical Center Rotterdam Use of cabazitaxel in the treatment of prostate cancer
MY197562A (en) 2015-09-21 2023-06-23 Aptevo Res & Development Llc Cd3 binding polypeptides
WO2017151836A1 (en) 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
EP4265257A1 (de) 2017-09-01 2023-10-25 East Carolina University Kombination eines prostaglandin-ethanolamids der j-serie und eines checkpoint-inhibitors zur verwendung bei der behandlung von krebs
CN114222803A (zh) 2019-05-20 2022-03-22 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US4086217A (en) * 1976-03-03 1978-04-25 Hoffmann-La Roche Inc. Carcinoembryonic antigens
US4228236A (en) * 1978-05-15 1980-10-14 Northwestern University Process of producing carcinoembryonic antigen

Also Published As

Publication number Publication date
CA1183451A (en) 1985-03-05
IL65915A0 (en) 1982-08-31
EP0066786A2 (de) 1982-12-15
DE3271119D1 (en) 1986-06-19
WO1982004263A1 (en) 1982-12-09
ATE19792T1 (de) 1986-05-15
AU8731882A (en) 1982-12-07
JPS58501355A (ja) 1983-08-18
EP0066786B1 (de) 1986-05-14
US4468457A (en) 1984-08-28
AU550306B2 (en) 1986-03-13
EP0066786A3 (en) 1983-07-20

Similar Documents

Publication Publication Date Title
IL65915A (en) Methods for producing a purified immunologically active tryptic peptide and for producing mono-specific antibodies to peptides prepared thereby
MY8600519A (en) Hybird cell line for producing monoclonal antibody to a human prothymocyte antigen antibody method of preparation of this antibody diagnostic and therapeutic uses and pharmaceutical compositions comprising this antibody
MY8600517A (en) Hybird cell line for producing complement-fixing, monoclonal antibody to human suppressor t cells antibody method of preparation of this antibody diagnostic anand therapeutic uses and pharmaceutical compositions comprising this antibody
IL86809A (en) Second generation monoclonal antibodies with binding specificity to tag-72, method for detecting human carcinomas utilizing the same, and pharmaceutical compositions containing the same
DE3070896D1 (en) Monoclonal antibody to human helper t cells, method of preparing it, hybrid cell line producing it, its diagnostic and therapeutic uses and diagnostic and therapeutic compositions comprising it
DE3170352D1 (en) Hybrid cell line for producing monoclonal antibody to a human t cell antigen, antibody, and methods
AU1198288A (en) Monoclonal antibodies against melanoma-associated antigens, hybrid cell lines producing these antibodies, and use therefor
MY8600535A (en) Monoclonal antibody to human t cells method for preparing it, hybird cell line producing it, therapeutic composition comprising it and diagnostic method using it.
EP0461177A4 (en) Human intra-acrosomal sperm antigen for use in a contraceptive vaccine
AU590656B2 (en) Anti cytomegaloviral human monoclonal antibody and process for its preparation
SE8103198L (sv) Forfarande for framstellning av antikroppar
NZ331557A (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
JPS5657753A (en) Novel glucagon fragment, and its use
ES443969A1 (es) Procedimiento de preparacion de un agente peptidico de regu-lacion de la glucemia.
EP0320866A3 (de) Schützendes immundominantes Epitop in der S1-Untereinheit von Pertussistoxin
JPS6445398A (en) Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
GB2199833A (en) Preparation of monoclonal antibodies
ES8802090A1 (es) Procedimiento inmunologico para la determinacion de la hormona estimuladora de foliculos
JPS5344620A (en) Recovering of immobilized vaccine and specific antigen
JPS5234668A (en) Gaseous phase growing process of semiconductor
DE3475309D1 (en) Synthetic peptide, immune globulin and process for immunizing a mammal
JPS5239670A (en) Process for synthesizing motilin
PT79232B (en) Process for producing immune interferon and of pharmaceutical compositions containing the same
JPS6471481A (en) Cell line producing monoclonal antibody and monoclonal antibody produced therefrom
IT1207163B (it) Procedimento per produrre anticorpi umani.